Improved adherence to statin treatment and differences in results between men and women after pictorial risk communication—a sub-study of the VIPVIZA RCT

IF 2.4 3区医学 Q3 PHARMACOLOGY & PHARMACY European Journal of Clinical Pharmacology Pub Date : 2024-04-29 DOI:10.1007/s00228-024-03694-6

Henrik Holmberg, Eva-Lotta Glader, Ulf Näslund, Bo Carlberg, Eva Sönnerstam, Margareta Norberg, Anders Själander

{"title":"Improved adherence to statin treatment and differences in results between men and women after pictorial risk communication—a sub-study of the VIPVIZA RCT","authors":"Henrik Holmberg, Eva-Lotta Glader, Ulf Näslund, Bo Carlberg, Eva Sönnerstam, Margareta Norberg, Anders Själander","doi":"10.1007/s00228-024-03694-6","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>People with intermediate CVD risk constitute most of the population. Within this group, the proportion of events is lower compared to the high-risk group, but they contribute with the largest absolute number of events. Atherosclerosis is a dynamic process and progression can be slowed or even reversed with medication and lifestyle changes, but adherence to prescribed treatment is crucial.</p><h3 data-test=\"abstract-sub-heading\">Aim</h3><p>To investigate the long-term effects of interventions with pictorial risk communication of cardiovascular (CVD) risk on average adherence in a group of statin users. Compare response in adherence over time between men and women after intervention.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Participants on active statin treatment were followed up to 5 years after being randomly assigned to an intervention program aimed at raising CVD risk awareness among participants and their physicians. Merging prescribed medication databases with VIPVIZA study to study adherence over time. A moving average adherence was used to compare groups.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Generally, the average adherence to statins among the 512 participants was high. Men had a higher average adherence over time, while women had a sharper increase in adherence in conjuncture with the intervention program.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Both men and women were receptive to pictorial information regarding CVD risk, but the intervention effect was more pronounced in women. Sex differences are important when considering risk communication strategies. Periodically repeating the intervention was beneficial for maintaining the intervention effect over time.</p><h3 data-test=\"abstract-sub-heading\">Trial registration</h3><p>The VIPVIZA study is registered with ClinicalTrials.gov, May 8, 2013, number NCT01849575.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-024-03694-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

People with intermediate CVD risk constitute most of the population. Within this group, the proportion of events is lower compared to the high-risk group, but they contribute with the largest absolute number of events. Atherosclerosis is a dynamic process and progression can be slowed or even reversed with medication and lifestyle changes, but adherence to prescribed treatment is crucial.

Aim

To investigate the long-term effects of interventions with pictorial risk communication of cardiovascular (CVD) risk on average adherence in a group of statin users. Compare response in adherence over time between men and women after intervention.

Methods

Participants on active statin treatment were followed up to 5 years after being randomly assigned to an intervention program aimed at raising CVD risk awareness among participants and their physicians. Merging prescribed medication databases with VIPVIZA study to study adherence over time. A moving average adherence was used to compare groups.

Results

Generally, the average adherence to statins among the 512 participants was high. Men had a higher average adherence over time, while women had a sharper increase in adherence in conjuncture with the intervention program.

Conclusions

Both men and women were receptive to pictorial information regarding CVD risk, but the intervention effect was more pronounced in women. Sex differences are important when considering risk communication strategies. Periodically repeating the intervention was beneficial for maintaining the intervention effect over time.

Trial registration

The VIPVIZA study is registered with ClinicalTrials.gov, May 8, 2013, number NCT01849575.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

图形化风险交流后他汀类药物治疗依从性的改善及男女之间的结果差异--VIPVIZA RCT 的子研究

背景中度心血管疾病风险人群占总人口的大多数。与高危人群相比，中危人群发生心血管疾病的比例较低，但他们发生心血管疾病的绝对数量最多。动脉粥样硬化是一个动态过程，通过药物治疗和生活方式的改变可以减缓甚至逆转病情的发展，但坚持处方治疗至关重要。方法对正在接受他汀类药物治疗的参与者进行长达5年的随访，此前他们被随机分配到一个旨在提高参与者及其医生对心血管疾病风险认识的干预项目中。将处方药数据库与VIPVIZA研究合并，研究随时间变化的依从性。结果总体而言，512 名参与者对他汀类药物的平均依从性较高。结论男性和女性都能接受有关心血管疾病风险的图像信息，但干预效果在女性中更为明显。在考虑风险交流策略时，性别差异非常重要。定期重复干预有利于长期保持干预效果。试验注册VIPVIZA研究已于2013年5月8日在ClinicalTrials.gov注册，编号为NCT01849575。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Clinical Pharmacology 医学-药学

CiteScore

5.40

自引率

3.40%

发文量

170

审稿时长

3-8 weeks

期刊介绍： The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed. Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor. Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves -a compound that is interesting and new in some basic or fundamental way, or -methods that are original in some basic sense, or -a highly unexpected outcome, or -conclusions that are scientifically novel in some basic or fundamental sense.